Please assess the completion status of the following clinical trial:

Trial Title: Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* For all patient :~  •Written informed consent~* For Cohort A :~  * Patient with hematological malignancy of high grade phenotype B (non Hodgkin's lymphoma diffuse large cell) or low grade (mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma or Waldenstrom disease), regardless the initial extension stage.~ * Histologically or cytologically and immunophenotypical confirmed~ * Patient candidate to a second-line or more therapy~ * First-line treatment with rituximab~* For Cohort B :~  * Absence of prior treatment with an anti-CD20 antibody~ * Histologically or cytologically and immunophenotypical confirmed~Exclusion Criteria:~* For all patients :~  * Patient with any medical or psychiatric condition or disease,~ * Patient under guardianship, curatorship or under the protection of justice and pregnant women~* For Cohort A :~  * Patient with chronic lymphocytic leukemia~ * Patient with indolent lymphoma relapsed more than 1 year after treatment with Rituximab~ * Patient allogeneic hematopoietic cells~ * Patient with linked lymphoproliferative syndrome with congenital immunosuppression (eg SCID, XLP ...) or acquired (post-transplant lymphoma)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: None): In Cohort A, patients will be included either in the group sustainable responseor in the short / refractory response group.~- sustainable response group : patient with NHL diffuse large B cells, and persistent complete response for at least 6 months after first-line treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease in complete response or partial stable response for at least 1 year after first line treatment with Rituximab~short / refractory response group : patient with NHL diffuse large B cells, refractory or relapsed in less than 6 months after at least one line of treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease refractory or relapsed / progression within less than 1 year after at least one line of treatment with Rituximab
- Cohort B (Type: None): For Cohort B patients will be included either in the group B hematologic therapeutic abstention or in the group any blood disease not treated with anti-CD20 antibodies.~B hematologic therapeutic abstention group : patient with hematological malignancy whatever the initial expansion stage~any blood disease not treated with anti-CD20 antibodies group : patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstorm disease without treatment criteria at diagnosis and with stable disease for at least 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).